New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
06:05 EDTPSTIPluristem's commercial scale cell manufacturing process approved by FDA
Pluristem Therapeutics announced that the FDA has reviewed Pluristem's comparability studies of its PLacental eXpanded, or PLX, cell products and granted approval for the company to manufacture these products in its new commercial-scale cell manufacturing facility. Pluristem has implemented its proprietary, fully automated 3D cell expansion manufacturing platform that uses its patented high-throughput culturing technologies, 3D bioreactors, and downstream equipment. Pluristem's facility has the ability to efficiently produce approximately 150,000 doses of PLX cells annually, with batch-to-batch consistency, which potentially translates into significant economic value.
News For PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
05:34 EDTPSTIPluristem Therapeutics reports new data shows PLX cells protect neurons
Pluristem Therapeutics announced that a study of PLacental eXpanded, or PLX, cells was accepted for publication in the February, 2015 issue of Biochimica et Biophysica Acta Molecular Cell Research. The study results show that PLX cells protect PC12 cells an established model of various nerve cells including dopaminergic neurons from death after oxygen and glucose deprivation. The protective effects of PLX cells were strongly correlated with the secretion of interleukin 6 and vascular endothelial growth factor, which are known to have neuroprotective effects in humans with injuries to the nervous system that can occur after events such as a stroke.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use